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Summary S9788 is a new triazineaminopiperidine derivate capable of reversing multidrug resistance (MDR) in cells resistant to 
chemotherapeutic agents such as doxorubicin. It does not belong to a known class of MDR revertants, but its action involves the binding of 
P-glycoprotein. Thirty-eight evaluable patients with advanced colorectal or renal cell cancer were treated with doxorubicin alone (16 patients) 
followed after disease progression with combination treatment of doxorubicin plus S9788 (12 patients) or upfront with the combination of 
doxorubicin plus S9788 (22 patients). S9788 was given i.v. as a loading dose of 56 mg n r2 over 30 min followed by doxorubicin given at 
50 mg nrr2 as a bolus infusion. Thereafter, a 2-h infusion of S9788 was administered at escalating doses ranging from 24 to 120 mg n r2 in 
subsequent cohorts of 4-10 patients. Pharmacokinetic analysis demonstrated that concentrations of S9788 that are known to reverse MDR 
in vitro were achieved in patients at non-toxic doses. Compared with treatment with doxorubicin alone, treatment with the combination of 
doxorubicin and S9788 produced a significant increase in the occurrence of WHO grade 3-4 granulocytopenia. Treatment with S9788 was 
cardiotoxic as it caused a dose-dependent and reversible increase in corrected QT intervals as well as clinically non-significant arrhythmias 
on 24- or 48-h Holter recordings. Although clinically relevant cardiac toxicities did not occur, the study was terminated as higher doses of 
S9788 may increase the risk of severe cardiac arrhythmias. Twenty-nine patients treated with S9788 plus doxorubicin were evaluable for 
response, and one patient, who progressed after treatment with doxorubicin alone, achieved a partial response. We conclude that S9788 
administered at the doses and schedule used in this study results in relevant plasma concentrations in humans and can safely be 
administered in combination with doxorubicin.
Inherent or acquired multidrug resistance (MDR) is an important Pierre et al, 1992). Structurally, S9788 does not belong to any o f  
cau se  o f  failure o f  cancer chemotherapy. Several mechanisms the classes of compounds known to reverse MDR. It increases the
responsible for M D R  have been described, and the most exten- intracellular accumulation and retention of doxorubicin,
s iv e ly  investigated is the expression o f  the product of the MDR1 vincristine and vinblastine in resistant cell lines displaying the P-
gen e , P-glycoprotein (P-gp) or P -1 7 0  (Roninson, 1992). This gp-mediated MDR phenotype (Leonce et al, 1992; Efferth
efflux et al, 1993; Hill et al, 1993; Huet et al, 1993; Julia et al, 1994;
cy to tox ic  agents, e .g . doxorubicin, vincristine, vinblastine and Merlin et al 1994). These studies also showed that modulation o f  
actinom ycin  D. Different compounds h a v e  been shown to reverse resistance is obtained in both drug-selected and inherently resis- 
P-gp-m ediated M D R , including c a lc iu m  channel antagonists tant cell lines, and that S9788 is more potent than verapamil at 
(verapam il), calmodulin inhibitors (q u in ine , quinidine), oestrogen equimolar concentrations. It has been hypothesized that, in acldi- 
receptor antagonists (tamoxifen), stero ids and immunomodulators tion to P-gp binding, S9788 may also act by altering the intraeel- 
(cyclosporin  A). T he mechanisms by w h ich  these drugs influence lular drug distribution (Merlin et al, 1994; Sebille et al, 1994). 
M D R  have not a lw ays been identified. The clinical use of these Although the optimum schedule has not yet been defined, a 
M D R  modulators is hampered by the to x ic  side-effects that occur prolonged infusion of S9788 starting before and maintained after 
w hen the suprapharmacological doses required to achieve signifi- the administration of chemotherapy appears to be more effective  
cant reversal of M D R  are used (P ennock  et al, 1991; Raderer and than a single-bolus infusion (Perez et al, 1993; Julia et al, 1994;
Soudon et al, 1995). S9788 has been shown not to interfere with 
doxorubicin plasma pharmacokinetics (de Valeriola et al, 1997).
search  foi 
importance
M DR
S 9 7 8 8  is a triazineaminopiperidine derivate capable of reversing Preliminary results of phase I studies of doxorubicin plus S9788 ,  
; the latter being infused over 30 min or 6 h, have shown cardiac
arrhythmias (mainly AV blocks, bradycardia, tachycardia), 
hypotension and prolongation of the QT interval on electrocar­
diograms in some patients (Awada et al, 1993; Clavel et al, 1993; 
Goncalves et al, 1995). Most of these cardiac toxicities were  
asymptomatic. This prompted us to keep patients under c 
cardiac surveillance in the present study. Only patients with
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advanced colorectal and renal cell cancer were included in the 
study as these types of cancer are resistant to anthraeyelins, with 
response rates o f 1%
1.8-4.2%) respectively
f
Cl 1.9-17%) and 2.9% Cl
prophylaxis before doxorubicin infusion. Dose-limiting toxicit} 
(DLT) was defined as any of the following events: (1) decrease > 
15% of ventricular ejection fraction; or (2 ) mucositis, cardiac, renal, 
hepatic, neurological or any major unexpected toxicity > WHO 
Although other mechanisms may play a role in their resistance grade 3. DLT occurring in two or more patients treated al the same 
to chemotherapy (Redmond el al, 1991; Chapman and Goldstein, dose level was considered as the clinical end point for this study. 
1995), tumour cells o f both these types o f cancer are known to 
express the MDR1 gene and contain high levels o f P-gp activity 
(Goldstein et al, 1989; Kanamaru et al, 1989; Lai et al, 1991;
Study monitoring
laboratory studies [complete blood cell count with leucocyte differ­
ential (weekly), prothrombin and partial thromboplastin limes.
Kramer et al, 1993), and this may therefore play a key role in their A complete history, physical examination, performance status and
resistance to anthraeyelins. The aims of the present study were to 
investigate the toxicity, anti-tumour activity and pharmacokinetics 
of S9788 administered before and after infusion of doxorubicin 
in patients with advanced colorectal and renal cell cancer. A 
suboptimal dose o f doxorubicin was chosen for this study
(50 mg m 2 once every 3 
potentiation of its side-effects by S9788.
ause o f the
blood urea nitrogen, serum electrolytes, creatinine, calcium, phos­
phorus, liver transaminases, total bilirubin, amylase, alkaline phos­
phatase and urinalysis] were obtained at baseline and before each 
cycle. Ventricular ejection fraction, determined by either ultrasound 
or nuclear scanning, was planned for each patient at baseline and 
after completion of every two cycles, ll was intended tlial all
MATERIALS AND METHODS
patients should have continuous cardiac telemetry and/or Holler 
recording for 24 h starting a minimum of 30 min before S978N
Inclusion criteria
Eligibility criteria included histological proof o f advanced colorectal 
or renal cell cancer with documented progression within the last 
months before entry into the study, measurable disease parameters, 
age between 18 and 75 years, Karnofsky performance status >80%, 
no radiotherapy, hormone therapy or immunotherapy during the last 
2 weeks and no chemotherapy during the last 4 weeks before study 
entry. Normal values for Hb, platelets, WBC and serum electrolytes 
were required. Liver transaminases were allowed to be < 2.5 times 
and bilirubin, amylase, creatinine and urea < 1.25 times the upper
infusion or doxorubicin alone. Determination of the maximum 
corrected QT intervals (QTc max) was performed according to the 
method described by Bazett (1920). QTc values of <440 ms 
were considered as normal. Twelve-lead electrocardiograms were 
performed before and directly after each cycle. Patients were evalu­
ated weekly for toxicity and every two cycles for response. Toxicity 
and response were scored according to WHO criteria. Cycles could 
only be repeated if granulocyte cell counts were >2000  x 10'1 1 1 
and in the absence of grade > 2 mucositis, renal, hepatic, neurolog­
ical or other haematological toxicity at the time o f  retreatment.
normal values, and creatinine clearance > 6 0  ml min '. Any history 
of significant cardiac arrhythmias, cardiac failure or recent myocar- Pharmacokinetic analysis
dial infarction was not allowed, and patients were required to have 
normal cardiac ventricular ejection fraction (>40%>). no clinical 
signs o f central nervous system metastasis, no concurrent use o f
Heparinized venous blood samples were collected before and at the 
end of the 30-min infusion of the loading dose o fS 9788  as well ns 
before and 1 h, 2 h, 2.5 h and 24 h after the start of the 2-h mainte-
other investigational or anti-neoplastic agents and no second malig- nance infusion of S9788. Samples were quickly centri fuged and 
nancy. Written informed consent was obtained from all patients. plasma was stored at -20°C until analysis. S9788 was quantitated 
Before initiation of this trial, institutional review board approval was by a specific high-performance liquid chromatographic method
obtained at each of the participating centres.
Study design and drug administration
(HPLC) as described previously (Bakes et al, 1993) using a solid* 
phase extraction procedure and a reversed-phase HPLC (Hypersil 
ODS) with ultraviolet detection (230 nm). The mean precision and 
accuracy were 5,0%' and 7.9%, respectively, over a range of 1
Patients were either initially treated with the combination of doxoru- 500 ng ml 1 with a quantification limit o f 1 ng ml '. S9788 plasma 
bicin and S9788, or after documented progression of disease on concentrations were modelled over time, using extended least
treatment with doxorubicin alone. This decision was left to the 
investigators of the various institutions, as some centres considered 
treatment of patients with colorectal and renal cell cancer with 
single-agent doxorubicin not acceptable. S9788 (6-4-|2,2-di(4-fluo-
rophenyl) ethylaminoj N,N'-di,2-propenyl 1,3,5-
squares regression on the computer program Micropluirm (S. Vrien. 
LOGINSERM) version 4.0. The two-compartment model was 
chosen using Akaike’s information criterion ( Yamaoka et al, I97S). 
The total body clearance (Cl, h 1 '), distribution volume al steady 
state (VUss, 1), distribution half-life (y1/ ,« ,  min) and elimination
triazine 2,4-diamine) was provided by IRIS (Courbevoie, France) half-life h) were estimated by the model, 
in 10-ml vials at a cohcentration o f  10 mg ml 1 formulated in a
bismethane sulphonate salt solution. The drug was diluted in either 
250 ml (loading dose) or 1000 ml (2-h infusion) of dextrose 5% in 
water. A fixed loading dose of S9788 at 56 mg nr- administered
Statistical methods
The correlation between dose o and QTc max was
over 30 min i.v. was followed by a 2-h infusion at different dose analysed using general linear models with the dose o f S9788 as the
levels starting at 24 mg nr2. Doxorubicin 50 mg nr- was adminis- main effect and the patient as the nested effect. The data from 63
tered over 5 min i.v. either alone or directly after the loading dose. A cycles in 26 patients were analysed. The difference in non-cardiac
minimum of three patients were entered at each 2-h infusion dose 
level of S9788. No intra-patient dose escalation was allowed. Cycles 
were repeated every 3 weeks. All patients received antiemetic
toxicities between treatment with doxorubicin and doxorubicin 
plus S9788 was analysed (a  = 0.05) using the two-sided chi-square 
and the Fisher’s exact tests,
© Cancer Research Campaign 1997 British Journal of Cancer (1997) 76(10), 1376-1381
1378 CJA Punt et al
Table 1 Dose escalation schedule of S9788
Dose level of 2-h infusion 
of S9788 (mg rrr2} Patients (n) Total number of cycles
24 4 12
48 6 13
72 9 29
96 10 26
120 5 9
Total 34 89
All patients received a loading dose of S9788 at 56 mg rrra i.v. in 30 min and 
doxorubicin at 50 mg rrr8 i.v. in 5 min prior to the 2-h infusion of S9788.
RESULTS
Patients characteristics
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A total of 39 patients were entered into the study in eight partici­
pating institutions. One patient was considered ineligible because 
o f pretreatment with doxorubicin at a cumulative dose o f  
490 mg nr2 and a previous second malignancy. The number of 
assessable patients was therefore 38: 27 patients with colorectal 
cancer and 11 with renal cell cancer. The median age was 61 years 
(range 34-74) and median Karnofsky performance score was 90% 
(range 80-100%). The 28 patients pretreated with chemotherapy 
had received a median of two (1-3) regimens. The majority o f  
these patients had received a 5-fluorouracil-containing regimen for 
colorectal cancer. Six o f  eleven patients with renal cell cancer had 
received prior immunotherapy.
Treatment
Sixteen patients started treatment with doxorubicin alone at 
50 mg ITT- and received a median of two (1-5) cycles. Of these,
12 patients later received combined treatment with S9788 plus 
doxorubicin. The reasons that four patients did not receive the 
combined treatment were death due to progressive disease ( 1), 
multiple ventricular extrasystoles during doxorubicin treatment 
( 1), patient refusal ( I ) and loss to follow-up ( 1). The remaining 22 
patients started treatment with the combination of S9788 with 
doxorubicin.
The number of patients treated at the different dose levels o f the 
2-h infusion o f  S9788 is shown in Table 1. A total of 34 patients 
received a median of two cycles (1-8) of S9788. The planned close 
for both drugs wtis respected in all patients but one, in whom the 
doxorubicin dose was reduced because o f  grade 3 stomatitis and 
grade 4 leucocytopenia. Although the clinical end point o f the 
study was not reached, the study was terminated because o f the 
occurrence of a torsade de pointe with syncope in a patient treated 
in another French phase I study at a S9788 dose that was lower 
than the doses that were used in our study (Terret et al, 1996).
Cardiac toxicity
N o major haemodynamic changes occurred in any patient during 
the study. No variation > 10% in the ventricular ejection fraction 
value was observed within individual patients. A total o f  87 Holter 
registrations (73 of 24-h and 14 o f  48-h) were obtained from 26 
patients. On 19 Holter recordings o f  seven patients during admin­
istration o f  doxorubicin alone, no arrhythmias or prolongation of
Figure 1. Correlation between QTc max values and S9788 dose levels of 
24 mg nr2 (n = 4), 48 mg rrr1-’ (n = 12), 72 mg nr2 (n = 19), 96 mg n ra 
(n = 22), and 120 mg nr2 (n = 6). S9788 at these dosages was administered 
as a 2-h infusion after a loading dose of S9788 at 56 mg rrr2 in 30 min 
followed by doxorubicin bolus infusion at 50 mg nr2. The correlation was 
significant with r=  0.38, P= 0.001 (general linear models)
QTc max > 440 ms were observed. Asymptomatic arrhythmias, 
occurring after the start of S9788 infusion and disappearing within 
18 h, were demonstrated on 21 out of 68 Holter recordings o f
13 out of 34 patients receiving doxorubicin plus S9788. The 
following arrhythmias (frequency of occurrence) were seen: 
Mobitz type I (1), Mobitz type II ( 1), third-degree atrioventricular 
block (2), non-sustained ventricular tachycardia (3), supraventric­
ular (8) and ventricular (4) extrasystoles, supraventricular tachy­
cardias of less than 30 s duration (6). These arrhythmias occurred 
at all dose levels of S9788 and were not consistently present during 
every cycle in individual patients. In patients receiving doxoru­
bicin plus S9788, the QTc max was < 440 ms in one patient, > 440  
and <, 600 ms in 20 patients, and > 600 ms in five patients, with a 
median value of 541 ms (range 404-685). QTc max occurred 
within 3 h after the start of S9788 infusion in 7 out o f 26 patients, 
between 3 and 6 h in 16 out of 26 patients, and after 6 h in 3 out of  
26 patients. There was a statistically significant corrrelation 
between the QTc max and the level of S9788 
(/• = 0.38, P = 0.001, Figure 1 ). An increase in the dose of S9788 o f  
24 mg nr2 increased the QTc max with an average of 21.5 ms. 
There was no correlation between the QTc max and the occurrence 
of arrhythmias. No cumulative effect of S9788 on the QTc max 
was seen, but a cumulative effect on the occurrence o f arrythmias 
could not be excluded.
Non-cardiac toxicity
These consisted of alopecia, nausea, vomiting, stomatitis, and 
myelosuppression, as might be expected from treatment with 
doxorubicin. Compared with treatment with doxorubicin alone, 
treatment with the combination of doxorubicin plus S9788 caused 
a significant increase in the number of patients experiencing WHO 
grade 3-4 granulocytopenia (Table 2). No episode of febrile 
neutropenia occurred in any patient. A cumulative effect of  
doxorubicin as a cause for this toxicity was unlikely, as the first 
appearance of grade 3 -4  granulocytopenia occurred during the
British Journal of Cancer (1997) 76(10), 1376-1381 © Cancer Research Campaign 1997
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Table 2 Non-cardiac toxicities
Toxicities WHO grade Doxorubicin Doxorubicin plus S9788 P-value overall/grade 3-4
Nausea 0 10 (62%) 10 (29%)
1/2 6 (38%) 24(71%)
3/4 0 0 0.06/1.0
Vomiting 0 12 (80%) 17 (50%)
1/2 2 (13%) 14(41%)
3/4 1 (7%) 3 (9%) 0.13/1.0
Stomatitis 0 16 (100%) 28 (82%)
1/2 0 3 (9%)
3/4 0 3 (9%) 0.20/0.61
Anaemia 0 12 (75%) 14 (47%)
1/2 4 (25%) 13 (43%)
3/4 0 3 ( 10%) 0.10/0.53
Leucopenia 0 4 (25%) 4 ( 14%)
1/2 10 (62%) 13 (45%)
3/4 2(13%) 12 (41%) 0.09/0.09
Granulocytopenia 0 5 (31%) 6 (22%)
1/2 8 (50%) 6 (22%)
3/4 3 (19%) 15 (56%) 0.05/0.04
Thrombocytopenia 0 15 (94%) 33 (97%)
1/2 1 (6%) 0
3/4 0 1 (3%) 0.27/1.0
The incidence of overall toxicity (three categories: grade 0, grade 1-2, grade 3-4) and of grade 3-4 toxicity in patients treated 
with doxorubicin vs doxorubicin plus S9788 was analysed two-sided (ex = 0.05) with the chi-square test (overall toxicity) and the 
exact test (grade 3-4 toxicity). A significant difference was noted in the incidence of grade 3-4 leucocytopenia and 
granulocytopenia. Numbers are patients.
1.2
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Figure 2. S9788 plasma concentration profile of a patient receiving S9788 
at a 30 min loading dose of 56 mg n r:i followed by a 5-min bolus infusion of 
doxorubicin and a S9788 2-h maintenance dose of 72 mg m s. x-axis, time 
from start infusion of loading dose of S9788; y-axis, S9788 concentration (hm)
first cycle of doxorubicin plus S9788 in 76% o f patients, and 5 out 
of 12 patients with grade 3 -4  leucocytopenia and 8 out of 15 
patients with grade 3 -4  granulocytopenia were not initially treated 
with cycles o f doxorubicin alone. No statistically significant 
differences were found between treatment with doxorubicin and 
with doxorubicin plus S9788 when overall toxicity was observed 
(Table 2). When the incidence of toxicity was compared with the 
number of cycles with and without S9788, a statistically signifi­
cant increase was also found in the incidence o f  nausea (grade 
1-2) and vomiting (grade 1-3) in cycles with doxorubicin plus 
S9788. Nausea increased from an incidence of 6 out o f 38 o f  
cycles with doxorubicin alone (16%) to 43 out o f  89 o f cycles with
doxorubicin plus S9788 (48%) (P = 0.001), and vomiting from 3 
out o f 38 cycles (8%) to 30 out o f  89 cycles (34%) (P =  0.005). No 
significant differences occurred in the incidence or grade of 
diarrhoea, hepatic or renal toxicity (data not shown).
S9788 pharmacokinetics
A total o f  eight patients were included in the pharmacokinetic 
study. All these patients received a loading dose o f  S9788 of 
56 mg n r 2 followed by doxorubicin infusion. Thereafter, three 
patients received a 2-h infusion o f  S9788 at 24 mg nr2, one patient 
at 48 mg nr2, two patients at 72 mg n r 2 and two patients at 
96 mg n r2. A typical plasma concentration profile o f S9788 over 
time is presented in Figure 2. The mean ± standard deviation (s.d.) 
of the maximum plasma concentration reached al the end of the 
56 mg n r2 loading dose was 1.31 ±  0.41 |iM (range 0 .73-2 .00 ). 
The maximum values for S9788 concentration during the 2-h 
maintenance infusion increased with the administration dose 
from 0.38 ± 0 .1 1 jam up to 1.05 ± 0.50 J.IM for 24 and 96 mg m •’ 
respectively. The mean ± s.d. pharmacokinetic parameters were 
as follows: Cl = 47 ± 181 h ', VUss = 669 ± 247 1. /'/,0c = 7 ± 5 min,
/'/,P 14 ± 10 h.
Clinical response
Of the 34 patients who received doxorubicin plus S9788, 29 were 
evaluable for response. Of these, one patient with colorectal cancer 
had a partial response of 6 months’ duration after disease progres­
sion on two cycles o f doxorubicin alone. Three patients (one 
•celai and two renal cell cancer) treated with doxorubicin plus 
had stable disease for 3, 4 and 7 months respectively. The 
emaining 25 patients had progressive disease.l
© Cancer Research Campaign 1997 British Journal of Cancer (1997) 76(10), 1376-1381
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DISCUSSION vary between ant* within individuals, and the QTc dispersion (i.e.
the distribution of repolarization on the heart) rather than the 
Clinical studies with MDR-modulating agents have shown disap- absolute value o f  QTc max may be considered as a risk factor for 
pointing results so far, mainly because of toxicities occurring at the occurrence of arrhythmias (Surawicz and Knoebel, 1984).
Moreover, in our study patients were not randomized for the 
different S9788 dose levels. In contrast, Terret et al (1996) found 
no correlation between QTc lengthening and dose of S9788 in
doses that were needed to achieve relevant plasma concentrations 
o f  the MDR modulator. Effective MDR reversal by S9788 in vitro
has been nning at concentrations o f 0.25 |AM
(Soudon et al, 1995). Therefore, this study shows that, using this other phase I studies. This might be explained by the above­
schedule, effective concentrations ol S9788 can be reached at non- mentioned reasons, and/or by the fact that other doses and
toxic doses in patients. The high total body clearance and short 
initial half-life o f S9788 that we found support the rationale for 
prolonged infusion over bolus infusion o f  S9788, as was suggested 
by others (Perez et al, 1993; Julia et al, 1994; Soudon et al, 1995). 
Compared with treatment with doxorubicin alone, patients treated 
with doxorubicin plus S9788 experienced a significant increase in 
the occurrence o f  WHO grade 3 -4  granulocytopenia, but not in the
occurrence or severity o f other toxicities. When toxicities were 
compared on a per cycle basis, there was also an increase in the 
occurrence o f  nausea and vomiting. A cumulative effect o f  doxoru­
bicin is unlikely as these toxicities mainly occurred during the first 
cycle o f  doxorubicin plus S9788, and occurred equally in patients 
initially treated with and without cycles of doxorubicin without 
S9788. A pharmacokinetic interaction between S9788 and doxoru­
bicin, as has been shown for instance for verapamil and epirubicin 
(Scheithauer et al, 1993) and cyclosporine and doxorubicin 
(Bartlett et al, 1994), can be excluded as the interference o f  S9788  
with the pharmacokinetics o f  doxorubicin has been investigated by 
the intra-individual comparisons o f  the pharmacokinetics parame­
ters o f doxorubicin obtained during two different cycles o f  doxoru­
bicin treatment without or with S9788 administration (de Valeriola 
et al, 1997). In this study, S9788 was not shown to 
interfere with doxorubicin pharmacokinetics.
The most common doxorubicin-induced cardiotoxicity is a 
cumulative dose-related myocardial cell damage that may result in 
congestive heart failure. Acute electrocardiographical changes 
and/or arrhythmias during and shortly after administration have 
also been described and consist primarily o f reversible non-specific 
S T -T  segment changes, sinus tachycardia, premature atrial and 
ventricular contractions, and decrease in voltage (Tokaz and Von 
Hoff, 1984). The incidence of these abnormalities ranges from 0 to 
41%. Prolongation o f  the QTc interval associated with arrhythmias 
has been described during anthracycline therapy in children and 
occurred more frequently in patients who received high cumulative 
doses (Bender et al, 1984; Schwartz et al, 1993). In this study, we 
found no electrocardiographical changes or arrhythmias in patients
with doxorubicin alone, for one patient who
experienced multiple ventricular exlrasysloles. However, in the 26 
patients of whom Holter recordings were available during treatment 
with the combination o f  doxorubicin and S9788, a prolongation o f  
QTc max and cardiac arrhythmias occurred in 25 out o f  26 and 13 
out o f  26 patients respectively. Although it has been demonstrated 
that Holter recordings o f healthy subjects show arrhythmias in a 
significant percentage (Stinson et al, 1995), a causal relationship 
between S9788 and these arrythmias seemed probable as they 
occurred after the start o f S9788 infusion and disappeared within 
18 h. A  correlation was established between the dose of S9788 and 
the prolongation o f  QTc max, although there was a high variation 
between individuals. There was no correlation between the dose of  
S9788 and the occurrence o f  arrhythmias. However, it should be
that this study did not have the appropriate design to establish 
these correlations for the following reasons: QTc max is known to
schedules o f S9788 were used. Although a predictive value of QTc 
lengthening for the occurrence of severe arrhythmias has never 
been established for values < 600 ms (Surawicz and Knoebel, 
1984), the study was terminated after the occurrence o f  severe 
cardiac arrhythmias (torsade de pointe with syncope) in another 
ongoing study with S9788 given over 6 h (Terret et al, 1996). Such 
a risk would preclude the routine use o f S9788.
The clinical activity o f  treatment with doxorubicin plus S9788 
was limited to one partial response in a patient with colorectal 
cancer, but a causative role o f S9788 was obvious as this patient 
had disease progression during prior treatment with doxorubicin 
alone. It should be noted that a suboptimal dose o f  doxorubicin 
was chosen for safety reasons.
In conclusion, we have safely administered a combination treat­
ment of doxorubicin and S9788 to 39 patients, and with the doses 
used relevant concentrations o f  S9788 were achieved. However, 
because o f  the unpredictable occurrence of cardiac arrhythmias, 
the company has decided to withdraw the drug S9788 from further
clinical development.
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